Key facts
- This page summarizes Julie Jordan's Form 4 filing for Neurogene Inc. (NGNE).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 30 Mar 2026, 17:38.
Julie Jordan - 26 Mar 2026 Form 4 Insider Report for Neurogene Inc. (NGNE)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- NGNE
- Reported as of
- 26 Mar 2026
- Net transaction value
- -$18,128
- SEC form
- 4
- Accepted by SEC
- 30 Mar 2026, 17:38:21 UTC
- Prior SEC filing
- 24 Feb 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Donna M. Cochener, as attorney-in-fact for Julie Jordan
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Julie Jordan filed Form 4 for Neurogene Inc. (NGNE) on 30 Mar 2026.
Change
- Previous filing in this sequence was filed on 24 Feb 2026.
- Current net transaction value: -$18,128.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001968554
Primary reporting owner
Jordan Julie
- Relationship
- Chief Medical Officer
- Address
- C/O NEUROGENE INC., 535 W 24TH STREET, 5TH FLOOR, NEW YORK
- Signature
- /s/ Donna M. Cochener, as attorney-in-fact for Julie Jordan
- Signature date
- 30 Mar 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NGNE
transaction
Common Stock
Sale
- Transaction value
- $18,128
- Shares
- -828
- Change %
- -6.2%
- Price
- $21.89
- Shares after
- 12,472
- Date
- 26 Mar 2026
- Ownership
- Direct
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 3 footnotes
Footnote F1
On March 26, 2026, a Restricted Stock Unit ("RSU") held by the Reporting Person vested in part. The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person. The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person. The sales reported on this Form 4 relate exclusively to this mandatory sale upon vesting of the RSU.
Footnote F2
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.68 to $22.19, inclusive. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F3
Consist of (a) 5,600 restricted stock units, which vest annually in equal installments on March 26, 2027 and March 26, 2028; and (b) 4,900 restricted stock units which vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029, in each case subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.